The FDA today approved omacetaxine mepesuccinate (Synribo) for the treatment of adults with chronic myeloid leukemia (CML) who are resistant to other therapies.
Radiotherapy directly after a prostatectomy in prostate cancer patients has long-term benefits, says a 10-year study. The study shows that radiation can prevent biochemical progression, as measured by rising prostate-specific antigen (PSA) levels.
Treatment of gastrointestinal stromal tumor (GIST) with regorafenib after prior treatment failure with both imatinib and sunitinib resulted in a PFS survival benefit for patients across all prespecified subgroups.
A new review of the literature shows that melanoma is substantially more common in immunosuppressed patients, including those with prior solid organ transplant and individuals with lymphoma.
Adolescents and young adults want to be more involved in specific aspects of their end-of-life care and found a planning document to aid in those decisions helpful, according to the results of a recently published study.
Stereotactic body radiation therapy is being compared to standard surgery in a phase III trial in high-risk operable patients with early-stage non–small-cell lung cancer.
The randomized COMPARZ trial of pazopanib vs sunitinib for metastatic renal cell carcinoma found a similar response to both, but pazopanib was more tolerable.
AVEO Pharmaceuticals Inc has announced that it has submitted a new drug application for tivozanib to the US Food and Drug Administration for the treatment of metastatic renal cell carcinoma.
A new imaging method--optical imaging mammography--is being developed as a tool that aims to provide a better way to identify breast cancer and to monitor patients’ responses to localized treatment.
Maintenance therapy with a new immunomodulator agent called MGN1703 improves progression-free survival over placebo in patients with metastatic colorectal cancer, according to a new study presented at the ESMO 2012 Congress.